Insider · CIK 0001205903
William H Rastetter
Files at NBIX (NEUROCRINE BIOSCIENCES INC), DARE (Dare Bioscience, Inc.), FATE (FATE THERAPEUTICS INC), RGLS (Regulus Therapeutics Inc.). First filing May 7, 2025, latest Nov 6, 2025.
William H Rastetter files SEC Form 4 as director at NBIX (NEUROCRINE BIOSCIENCES INC), and also at DARE (Dare Bioscience, Inc.), FATE (FATE THERAPEUTICS INC), RGLS (Regulus Therapeutics Inc.). Since May 7, 2025, William H Rastetter has reported 0 open-market buys worth $0 and 2 open-market sells worth $6.0M, the latest filed on Nov 6, 2025.
A track record needs three past buys with six months of prices behind them; William H Rastetter has 0, so none is measured yet.
The newest scored trade: sold $2.7M of NBIX on Nov 5, 2025, filed Nov 6, 2025, scored 23 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $2.7M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NBIX: NEUROCRINE BIOSCIENCES INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | NEUROCRINE BIOSCIENCES INC | $2.7M 18,000 shares | -31% | +76% from low0% from high | |
| 15Weak | NEUROCRINE BIOSCIENCES INC | $3.3M 30,000 shares | -44% | +25% from low-28% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Nov 5, 2025 | NBIX NEUROCRINE BIOSCIENCES, INC. | 18,000 0.02% of outstanding | $2.6M | Nov 5, 2025 | none |
| May 5, 2025 | NBIX NEUROCRINE BIOSCIENCES,INC. | 30,000 0.03% of outstanding | $3.3M | May 5, 2025 | none |
Transactions
Every row this insider has filed, 29 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | FATE FATE THERAPEUTICS INC | AGrant or award Stock Option (Right to Buy)derivative | +87,900 | $0.00 | $0 | 87,900 | Jun 15, 2026 |
| Jun 11, 2026 | DARE Dare Bioscience, Inc. | AGrant or award Stock Option (right to buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jun 11, 2026 |
| May 27, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | AGrant or award Restriced Stock Unitderivative | +2,567 | $0.00 | $0 | 2,567 | May 29, 2026 |
| May 21, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Common Stock | +3,318 | $0.00 | $0 | 43,678 | May 21, 2026 |
| May 21, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Restricted Stock Unitderivative | -3,318 | $0.00 | $0 | 0 | May 21, 2026 |
| May 5, 2026 | FATE FATE THERAPEUTICS INC | MOption exercise Common Stock | +25,000 | $1.69 | $42k | 36,331 | May 6, 2026 |
| May 5, 2026 | FATE FATE THERAPEUTICS INC | MOption exercise Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 0 | May 6, 2026 |
| Nov 5, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Common Stock10b5-1 | +18,000 | $47.89 | $862k | 58,360 | Nov 6, 2025 |
| Nov 5, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | SOpen-market sale Common Stock10b5-1 | -18,000 | $151.82 | $2.7M | 40,360 | Nov 6, 2025 |
| Nov 5, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Non-Qualified Stock Optionderivative10b5-1 | -18,000 | $0.00 | $0 | 0 | Nov 6, 2025 |
| Jul 9, 2025 | DARE Dare Bioscience, Inc. | AGrant or award Stock Option (right to buy)derivative | +4,500 | $0.00 | $0 | 4,500 | Jul 10, 2025 |
| Jun 25, 2025 | RGLS Regulus Therapeutics Inc. | UTender of shares Common Stockindirect: By The Rastetter Family Trust | -44,264 | - | - | 57,292 | Jun 27, 2025 |
| Jun 25, 2025 | RGLS Regulus Therapeutics Inc. | DDisposition to issuer Common Stockindirect: By The Rastetter Family Trust | -57,292 | - | - | 0 | Jun 27, 2025 |
| Jun 25, 2025 | RGLS Regulus Therapeutics Inc. | DDisposition to issuer Stock Optionderivativeindirect: By The Rastetter Family Trust | -4,650 | - | - | 0 | Jun 27, 2025 |
| Jun 25, 2025 | RGLS Regulus Therapeutics Inc. | DDisposition to issuer Stock Optionderivativeindirect: By The Rastetter Family Trust | -2,325 | - | - | 0 | Jun 27, 2025 |
| Jun 25, 2025 | RGLS Regulus Therapeutics Inc. | DDisposition to issuer Stock Optionderivativeindirect: By The Rastetter Family Trust | -4,000 | - | - | 0 | Jun 27, 2025 |
| Jun 25, 2025 | RGLS Regulus Therapeutics Inc. | DDisposition to issuer Stock Optionderivativeindirect: By The Rastetter Family Trust | -9,000 | - | - | 0 | Jun 27, 2025 |
| Jun 25, 2025 | RGLS Regulus Therapeutics Inc. | DDisposition to issuer Stock Optionderivativeindirect: By The Rastetter Family Trust | -30,000 | - | - | 0 | Jun 27, 2025 |
| Jun 25, 2025 | RGLS Regulus Therapeutics Inc. | DDisposition to issuer Stock Optionderivativeindirect: By The Rastetter Family Trust | -15,000 | - | - | 0 | Jun 27, 2025 |
| Jun 25, 2025 | RGLS Regulus Therapeutics Inc. | DDisposition to issuer Stock Optionderivativeindirect: By The Rastetter Family Trust | -30,000 | - | - | 0 | Jun 27, 2025 |
| Jun 25, 2025 | RGLS Regulus Therapeutics Inc. | DDisposition to issuer Stock Optionderivativeindirect: By The Rastetter Family Trust | -60,000 | - | - | 0 | Jun 27, 2025 |
| May 29, 2025 | FATE FATE THERAPEUTICS INC | AGrant or award Stock Option (Right to Buy)derivative | +55,000 | $0.00 | $0 | 55,000 | May 30, 2025 |
| May 22, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Common Stock | +2,869 | $0.00 | $0 | 40,360 | May 22, 2025 |
| May 21, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | AGrant or award Restricted Stock Unitderivative | +3,318 | $0.00 | $0 | 3,318 | May 22, 2025 |
| May 22, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Restricted Stock Unitderivative | -2,869 | $0.00 | $0 | 0 | May 22, 2025 |
| May 5, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Common Stock10b5-1 | +30,000 | $42.76 | $1.3M | 67,491 | May 7, 2025 |
| May 5, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | SOpen-market sale Common Stock10b5-1 | -30,000 | $110.20 | $3.3M | 37,491 | May 7, 2025 |
| May 5, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Non-Qualified Stock Optionderivative10b5-1 | -30,000 | $0.00 | $0 | 0 | May 7, 2025 |
| Apr 30, 2025 | RGLS Regulus Therapeutics Inc. | AGrant or award Common Stockindirect: The Rastetter Family Trust | +62,500 | $0.00 | $0 | 101,556 | Apr 30, 2025 |
Questions about William H Rastetter
Answered from the filings on this page, as of the latest one.
Is William H Rastetter buying or selling?
In the last 12 months William H Rastetter reported 0 open-market buys worth $0 and 1 open-market sell worth $2.7M on SEC Form 4; the latest was sold $2.7M of NBIX on Nov 5, 2025. Grants, option exercises and tax withholding are not counted.
How did William H Rastetter's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and William H Rastetter has 0.
Where does William H Rastetter file Form 4?
William H Rastetter has filed Form 4 at NBIX (NEUROCRINE BIOSCIENCES INC); DARE (Dare Bioscience, Inc.); FATE (FATE THERAPEUTICS INC); RGLS (Regulus Therapeutics Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.